The metabolic and hormonal effects of continuous subcutaneous insulin infusion therapy in diabetic children

G Soltész1, D Molnár, T Decsi

  • 1Department of Paediatrics, University of Pécs, Hungary.

Diabetologia
|January 1, 1988
PubMed

Insights

Insulin pump therapy in diabetic children normalizes many metabolic issues but can lead to low glucagon and ketones. Optimal glycemic control may require increased insulin action, with some hormonal imbalances persisting.

Area of Science:

  • Pediatric Endocrinology
  • Metabolic Disorders
  • Diabetes Management

Background:

  • Children with diabetes exhibit concurrent metabolic and hormonal abnormalities.
  • Achieving normoglycaemia (normal blood glucose) is a key treatment goal.

Purpose of the Study:

  • To evaluate the correction of metabolic and hormonal abnormalities in diabetic children treated with insulin pumps.
  • To assess fasting and postprandial hormonal and metabolic changes during insulin pump therapy.

Main Methods:

  • Two groups of diabetic children (newly-diagnosed and chronically-treated) received insulin pump therapy for 8-10 days.
  • Fasting and postprandial levels of metabolites, lipids, and hormones were measured before and after treatment.
  • A test meal was administered to evaluate immediate postprandial changes.

Main Results:

  • Insulin pump therapy normalized fasting levels of free insulin, growth hormone, free fatty acids, triglycerides, and total cholesterol.
  • Hypoglucagonaemia and hypoketonaemia were observed, particularly in newly-diagnosed children.
  • Lipid profiles showed varied changes in HDL subfractions between the two groups.
  • Postprandial hormonal and metabolic profiles suggested increased insulin action despite normal insulin levels.

Conclusions:

  • Insulin pump therapy corrects many metabolic abnormalities associated with diabetes in children.
  • Optimal glycemic control may be achieved at the cost of hormonal shifts, such as reduced glucagon and ketone levels.
  • Complete normalization of the metabolic and endocrine environment may not be fully attainable with insulin pump therapy alone.

Related Concept Videos

Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...